Tizona Therapeutics
Tizona Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class cancer immunotherapies by translating novel scientific insights into new medicines. Its lead program, TTX-080, is a first-in-class HLA-G antagonist in clinical trials for advanced solid tumors. Tizona is a portfolio company of Canaan Partners. As a pharmaceutical drug-development company it publishes no public developer API, developer portal, SDKs, or other machine-readable API surface; this profile is retained as a network company record rather than an API provider.
Tizona Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Immuno-Oncology, and Cancer Immunotherapy.
Kin Score
Resources
Company 1
The organization behind the API